期刊
CELL HOST & MICROBE
卷 4, 期 3, 页码 219-228出版社
CELL PRESS
DOI: 10.1016/j.chom.2008.08.002
关键词
-
资金
- Bill & Melinda Gates Foundation [37772]
- Design and Testing of Vaccine Candidates against Tuberculosis (TBVAC)
- MUVAPRED (Micosal Vaccines for Poverty Related Diseases)
- Sonderforschungsbereich Protektive und pathologische Folgen der Antigen-Verarbeitung [421]
- Bundesministerium fur Bildung und Forschung Networks PathoGenoMikPlus
- Nationales Genomforschungsnetz (NGFN)
In Africa, more than 4 million people suffer from active tuberculosis (TB) resulting in an estimated 650,000 deaths every year. The etiologic agent of TB, Mycobacterium tuberculosis, survives in resting macrophages, which control the pathogen after activation by specific T lymphocytes. Here, we describe the basic mechanisms underlying the host response to TB with an emphasis on immunity and discuss diagnostics, drugs, and vaccines for TB. Moreover, we outline our attempts to develop biomarkers, which could help the monitoring of TB clinical trials, provide the basis for new diagnostics, and allow prognosis of outcome of infection and of drug treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据